Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction

被引：0

作者：

Profili, Nicia I. ^{[1
]}

Castelli, Roberto ^{[1
]}

Manetti, Roberto ^{[1
]}

Sircana, Marta C. ^{[1
]}

Pagni, Michela ^{[1
]}

Sechi, Gemma Lisa ^{[1
]}

Gidaro, Antonio ^{[2
]}

Cossu, Costantino ^{[3
]}

Bella, Francesco ^{[3
]}

Delitala, Alessandro P. ^{[1
]}

机构：

[1] Univ Sassari, Dept Med Surg & Pharm, I-07100 Sassari, Italy

[2] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, I-20157 Milan, Italy

[3] Azienda Osped Univ Sassari, I-07100 Sassari, Italy

来源：

BIOMEDICINES | 2025年 / 13卷 / 03期

关键词：

SGLT2i; sodium-glucose cotransporter-2 inhibitors; acute myocardial infarction; acute heart failure; diabetes; cardiovascular disease; HEART-RATE-VARIABILITY; SGLT2; INHIBITORS; KIDNEY; DAPAGLIFLOZIN;

D O I：

10.3390/biomedicines13030720

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention.

引用

页数：13

共 66 条

[1] Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention [J].

Adel, Seyed Mohammad H. ;

Jorfi, Fateme ;

Mombeini, Hoda ;

Rashidi, Homeira ;

Fazeli, Saad .

SAUDI MEDICAL JOURNAL, 2022, 43 (05) :458-464

[2] Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure [J].

Attachaipanich, Tanawat ;

Chattipakorn, Siriporn C. ;

Chattipakorn, Nipon .

JOURNAL OF CELLULAR PHYSIOLOGY, 2022, 237 (05) :2404-2419

[3] Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis [J].

Basutkar, Roopa Satyanarayan ;

Cutinha, Rasheal Maria ;

Sathish, Varshini ;

Shahil, Aboobacker ;

Saneen, C. K. Najad .

CURRENT DIABETES REVIEWS, 2025, 21 (09)

[4] Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial [J].

Benedikt, Martin ;

Mangge, Harald ;

Aziz, Faisal ;

Curcic, Pero ;

Pailer, Sabine ;

Herrmann, Markus ;

Kolesnik, Ewald ;

Tripolt, Norbert J. ;

Pferschy, Peter N. ;

Wallner, Markus ;

Zirlik, Andreas ;

Sourij, Harald ;

von Lewinski, Dirk .

CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)

[5] Empagliflozin after Acute Myocardial Infarction [J].

Butler, Javed ;

Jones, W. Schuyler ;

Udell, Jacob A. ;

Anker, Stefan D. ;

Petrie, Mark C. ;

Harrington, Josephine ;

Mattheus, Michaela ;

Zwiener, Isabella ;

Amir, Offer ;

Bahit, M. Cecilia ;

Bauersachs, Johann ;

Bayes-Genis, Antoni ;

Chen, Yundai ;

Chopra, Vijay K. ;

Figtree, Gemma ;

Ge, Junbo ;

Goodman, Shaun G. ;

Gotcheva, Nina ;

Goto, Shinya ;

Gasior, Tomasz ;

Jamal, Waheed ;

Januzzi, James L. ;

Jeong, Myung Ho ;

Lopatin, Yuri ;

Lopes, Renato D. ;

Merkely, Bela ;

Parikh, Puja B. ;

Parkhomenko, Alexander ;

Ponikowski, Piotr ;

Rossello, Xavier ;

Schou, Morten ;

Simic, Dragan ;

Steg, P. Gabriel ;

Szachniewicz, Joanna ;

van der Meer, Peter ;

Vinereanu, Dragos ;

Zieroth, Shelley ;

Brueckmann, Martina ;

Sumin, Mikhail ;

Bhatt, Deepak L. ;

Hernandez, Adrian F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (16) :1455-1466

[6]

Byrne RA, 2024, EUR HEART J-ACUTE CA, V13, P55, DOI 10.1093/ehjacc/zuad107

[7] Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients [J].

Cai, Dabei ;

Chen, Qianwen ;

Mao, Lipeng ;

Xiao, Tingting ;

Wang, Yu ;

Gu, Qingqing ;

Wang, Qingjie ;

Ji, Yuan ;

Sun, Ling .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) :613-620

[8]

Camm AJ, 1996, CIRCULATION, V93, P1043

[9] Mortality in patients after a recent myocardial infarction - A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification [J].

Camm, AJ ;

Pratt, CM ;

Schwartz, PJ ;

Al-Khalidi, HR ;

Spyt, MJ ;

Holroyde, MJ ;

Karam, R ;

Sonnenblick, EH ;

Brum, JMG .

CIRCULATION, 2004, 109 (08) :990-996

[10] Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease [J].

Cannizzaro, Miryam ;

Jarosova, Jana ;

De Paepe, Boel .

JOURNAL OF APPLIED GENETICS, 2019, 60 (3-4) :305-317

← 1 2 3 4 5 6 7 →